Circulating soluble LR11, a novel marker of smooth muscle cell proliferation, is enhanced after coronary stenting in response to vascular injury.

OBJECTIVE Restenosis after vascular intervention remains a major clinical problem. Circulating LR11 has been shown a novel marker of intimal smooth muscle cell (SMC) proliferation in human and animal studies. The present study was performed to clarify the clinical significance of circulating LR11 in patients with stable angina pectoris after coronary stenting. METHODS AND RESULTS We firstly investigated the circulating sLR11 levels for 28 days after arterial injury in mice, and then assessed time-dependent change in circulating sLR11 level after coronary stenting in a clinical study. Mouse sLR11 levels rapidly increased to 4.0-fold of the control value without cuff placement at postoperative day (POD) 14, and the levels gradually declined to 3.1-fold of the control value until POD 28 in mice. The circulating soluble LR11 levels were measured (before and at 14, 60 and 240 days after coronary stenting in a clinical study of 102 consecutive patients with stable angina pectoris who were treated with percutaneous coronary intervention. Circulating sLR11 levels were significantly increased on days 14 and 60 after the procedure and positively associated with the angiographic late loss index. CONCLUSIONS Our study suggested that circulating sLR11 levels may be a potential marker for angiographic late loss in patients after coronary stenting. Further mechanistic studies are expected to know the clinical significance of sLR11 as a novel marker for intimal SMC.

[1]  S. Schwartz.  Smooth muscle migration in atherosclerosis and restenosis. , 1997, The Journal of clinical investigation.

[2]  A. Curcio,et al.  A new rat model of small vessel stenting , 2000, Basic Research in Cardiology.

[3]  C M Gibson,et al.  Generalized model of restenosis after conventional balloon angioplasty, stenting and directional atherectomy. , 1993, Journal of the American College of Cardiology.

[4]  P. Serruys,et al.  Delineating the Numerous Causes of Drug-Eluting Stent Restenosis , 2011 .

[5]  R. Virmani,et al.  Morphologic characteristics of lesion formation and time course of smooth muscle cell proliferation in a porcine proliferative restenosis model. , 1994, Journal of the American College of Cardiology.

[6]  Gregg W Stone,et al.  A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. , 2004, The New England journal of medicine.

[7]  K. Shirai,et al.  Enhanced circulating soluble LR11 in patients with coronary organic stenosis. , 2010, Atherosclerosis.

[8]  A. Curcio,et al.  Mechanisms of smooth muscle cell proliferation and endothelial regeneration after vascular injury and stenting: approach to therapy. , 2011, Circulation journal : official journal of the Japanese Circulation Society.

[9]  Hiroyuki Ebinuma,et al.  Development of an immunoassay for the quantification of soluble LR11, a circulating marker of atherosclerosis. , 2009, Clinical chemistry.

[10]  M. Aikawa,et al.  Intimal smooth muscle cells: the context-dependent origin. , 2010, Circulation.

[11]  V. Fuster,et al.  Management of restenosis after coronary intervention. , 1996, American heart journal.

[12]  Michael Joner,et al.  Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. , 2006, Journal of the American College of Cardiology.

[13]  S. Schwartz.  Perspectives series: cell adhesion in vascular biology. Smooth muscle migration in atherosclerosis and restenosis. , 1997 .

[14]  W. Schneider,et al.  LR11, an LDL Receptor Gene Family Member, Is a Novel Regulator of Smooth Muscle Cell Migration , 2004, Circulation research.

[15]  M. Nobuyoshi,et al.  Serial angiographic follow-up after Palmaz-Schatz stent implantation: comparison with conventional balloon angioplasty. , 1993, Journal of the American College of Cardiology.

[16]  P. Levendag,et al.  Clinical and angiographical follow-up after implantation of a 6--12 microCi radioactive stent in patients with coronary artery disease. , 2001, European heart journal.

[17]  M. Nobuyoshi,et al.  Restenosis after successful percutaneous transluminal coronary angioplasty: serial angiographic follow-up of 229 patients. , 1988, Journal of the American College of Cardiology.

[18]  Y. Yazaki,et al.  Redifferentiation of smooth muscle cells after coronary angioplasty determined via myosin heavy chain expression. , 1997, Circulation.

[19]  P. Serruys,et al.  Coronary stents: current status. , 2010, Journal of the American College of Cardiology.

[20]  Richard G. W. Anderson,et al.  LRP: Role in Vascular Wall Integrity and Protection from Atherosclerosis , 2003, Science.

[21]  Y. Hayashi,et al.  Incidence and risk factors of late target lesion revascularization after sirolimus-eluting stent implantation (3-year follow-up of the j-Cypher Registry). , 2010, The American journal of cardiology.

[22]  P. Serruys,et al.  A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. , 2002, The New England journal of medicine.

[23]  W. Schneider,et al.  Expression of LR11, a mosaic LDL receptor family member, is markedly increased in atherosclerotic lesions. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[24]  J. Jukema,et al.  Restenosis after PCI. Part 1: pathophysiology and risk factors , 2012, Nature Reviews Cardiology.

[25]  D. Sedding,et al.  Time-Course Analysis on the Differentiation of Bone Marrow-Derived Progenitor Cells Into Smooth Muscle Cells During Neointima Formation , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[26]  K. Karsch,et al.  Time course of smooth muscle cell proliferation in the intima and media of arteries following experimental angioplasty. , 1990, Circulation research.

[27]  W. Schneider,et al.  Enhanced Expression of the LDL Receptor Family Member LR11 Increases Migration of Smooth Muscle Cells In Vitro , 2002, Circulation.

[28]  Renu Virmani,et al.  Morphological Predictors of Restenosis After Coronary Stenting in Humans , 2002, Circulation.

[29]  W. Schneider,et al.  Pitavastatin attenuates the PDGF-induced LR11/uPA receptor-mediated migration of smooth muscle cells. , 2006, Biochemical and biophysical research communications.

[30]  W. Schneider,et al.  Ang II-stimulated migration of vascular smooth muscle cells is dependent on LR11 in mice. , 2008, The Journal of clinical investigation.

[31]  H. Bujo,et al.  Modulation of smooth muscle cell migration by members of the low-density lipoprotein receptor family. , 2006, Arteriosclerosis, Thrombosis and Vascular Biology.